Shari Goldfarb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shari Goldfarb has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Jeanne Carter
Departments of Surgery and Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY
2 shared publicationsJoanne Kelvin
Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publicationsMaura Dickler
Department of Medicine, Weill Cornell Medical College, New York, NY.; Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY
2 shared publications- Angelena Crown
Breast Surgery, True Family Women's Cancer Center, Swedish Cancer Institute, Seattle, WA, USA
1 shared publication Barbara L. Andersen
The Ohio State University, Department of Psychology
1 shared publicationBarry S. Komm
Sermonix Pharmaceuticals, Columbus, OH
1 shared publication
Latest Publications
- 23 April 2025
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (S1) , 1-8
Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment
Purpose Approximately 19% of breast cancer cases in 2020 were diagnosed in women under age 50. These premenopausal women with early-stage breast cancer face unique challenges related to family building. This study examines the decision-making and outcomes of patients who pursue fertility preservation before treatment and family building afterwards. Methods Breast cancer survivors seen by a fertility nurse specialist before initiating cancer treatment at Memorial Sloan Kettering Cancer Center (MSKCC) between 2009 and 2017 were contacted to participate. Participants completed a web-based cross-sectional survey examining decisions made about fertility preservation, factors influencing them, and post-treatment reflections and outcomes. Results Prior to treatment, 168 women met with a reproductive endocrinologist and 116 underwent fertility preservation. After completing cancer treatment, 36 women had children and 15 of these women used eggs/embryos frozen prior to treatment. The majority of women deemed these factors “very important” when deciding whether to freeze eggs/embryos: a desire to have a biologic child, the ability to feel hopeful about their future, the chance of success, feeling overwhelmed by their diagnosis, and concerns about having regret if they didn’t freeze their eggs/embryo. Conclusions Over half of patients who attempted family building after treatment were able to have children. Many of these women used eggs/embryos frozen before treatment either by getting pregnant themselves or via surrogacy. Implications for Cancer Survivors This data stresses the importance of referring cancer patients early to a reproductive endocrinologist before initiation of systemic therapy and has high translational promise in the clinical care of all young female cancer survivors interested in fertility preservation.
- 23 April 2025
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (S1) , 1-8
Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment
Purpose Approximately 19% of breast cancer cases in 2020 were diagnosed in women under age 50. These premenopausal women with early-stage breast cancer face unique challenges related to family building. This study examines the decision-making and outcomes of patients who pursue fertility preservation before treatment and family building afterwards. Methods Breast cancer survivors seen by a fertility nurse specialist before initiating cancer treatment at Memorial Sloan Kettering Cancer Center (MSKCC) between 2009 and 2017 were contacted to participate. Participants completed a web-based cross-sectional survey examining decisions made about fertility preservation, factors influencing them, and post-treatment reflections and outcomes. Results Prior to treatment, 168 women met with a reproductive endocrinologist and 116 underwent fertility preservation. After completing cancer treatment, 36 women had children and 15 of these women used eggs/embryos frozen prior to treatment. The majority of women deemed these factors “very important” when deciding whether to freeze eggs/embryos: a desire to have a biologic child, the ability to feel hopeful about their future, the chance of success, feeling overwhelmed by their diagnosis, and concerns about having regret if they didn’t freeze their eggs/embryo. Conclusions Over half of patients who attempted family building after treatment were able to have children. Many of these women used eggs/embryos frozen before treatment either by getting pregnant themselves or via surrogacy. Implications for Cancer Survivors This data stresses the importance of referring cancer patients early to a reproductive endocrinologist before initiation of systemic therapy and has high translational promise in the clinical care of all young female cancer survivors interested in fertility preservation.
- Open Access
- 13 December 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (3) , 261-267.e1
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study
- 13 December 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (3) , 261-267.e1
Open AccessEffects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 18 November 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 186 (1) , 107-114
A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia
Purpose Chemotherapy-induced alopecia (CIA) negatively affects psychosocial health and quality of life (QoL). Currently, there are no approved pharmacologic agents to prevent CIA. Here, we evaluated the safety, tolerability, and potential signal of efficacy of topical calcitriol (BPM31543) on CIA prevention. Materials and methods This Phase 1 trial included 23 female patients with breast cancer, gynecologic cancer, or sarcomas receiving a taxane-based chemotherapy. Patients received a 3 + 3 dose-escalation regimen at 5, 10, 20, 40, 60, and 80 μg/mL, with 3–6 patients per group. Patients applied topical BPM31543 to the scalp twice a day for 2 weeks prior to chemotherapy and continued until chemotherapy treatment was completed. The maximum tolerated dose (MTD) during first 28 day application was determined. Adverse event (AE) monitoring, pharmacokinetics, blinded photographic assessments, and patient self-assessment were evaluated. Results Out of 23 patients treated with BPM31543, 8 patients experienced at least 1 treatment-related adverse event (AE). The majority of AEs were mild to moderate in severity. Only 1 patient experienced SAEs (vomiting, nausea, fever, and flank pain) considered treatment related. Alopecia < 50% from baseline was observed in 8 patients at Week 7, and, of which 2 patients had < 50% alopecia maintained at Week 15. There were no detectable effects of topical BPM31543 on serum levels of calcitriol. Conclusions BPM31543 applied topically twice daily to the scalp is safe and well tolerated in patients receiving taxane-based chemotherapy. No DLT was observed at up to 80 µg/mL, and MTD was not reached. Based on the data from this trial, BPM31543 represents a promising therapy and warrants further investigation in Phase 2/3 trials.
- 18 November 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 186 (1) , 107-114
A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia
Purpose Chemotherapy-induced alopecia (CIA) negatively affects psychosocial health and quality of life (QoL). Currently, there are no approved pharmacologic agents to prevent CIA. Here, we evaluated the safety, tolerability, and potential signal of efficacy of topical calcitriol (BPM31543) on CIA prevention. Materials and methods This Phase 1 trial included 23 female patients with breast cancer, gynecologic cancer, or sarcomas receiving a taxane-based chemotherapy. Patients received a 3 + 3 dose-escalation regimen at 5, 10, 20, 40, 60, and 80 μg/mL, with 3–6 patients per group. Patients applied topical BPM31543 to the scalp twice a day for 2 weeks prior to chemotherapy and continued until chemotherapy treatment was completed. The maximum tolerated dose (MTD) during first 28 day application was determined. Adverse event (AE) monitoring, pharmacokinetics, blinded photographic assessments, and patient self-assessment were evaluated. Results Out of 23 patients treated with BPM31543, 8 patients experienced at least 1 treatment-related adverse event (AE). The majority of AEs were mild to moderate in severity. Only 1 patient experienced SAEs (vomiting, nausea, fever, and flank pain) considered treatment related. Alopecia < 50% from baseline was observed in 8 patients at Week 7, and, of which 2 patients had < 50% alopecia maintained at Week 15. There were no detectable effects of topical BPM31543 on serum levels of calcitriol. Conclusions BPM31543 applied topically twice daily to the scalp is safe and well tolerated in patients receiving taxane-based chemotherapy. No DLT was observed at up to 80 µg/mL, and MTD was not reached. Based on the data from this trial, BPM31543 represents a promising therapy and warrants further investigation in Phase 2/3 trials.
- Open Access
LONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
Background: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer. Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI. Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery. Conclusions: Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.
Open AccessLONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
Background: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer. Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI. Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery. Conclusions: Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.
- 15 January 2016
- Published by Springer Nature in Current Oncology Reports
- Vol. 18 (2) , 1-6
Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care
Treatment-related sexual complications are common in cancer patients although rarely discussed in the palliative care setting. Sexuality is an important survivorship issue and remains relevant even in the terminal setting. There are multiple barriers in dialoguing about intimacy and sexual functioning from the patient and provider perspectives. Palliative care providers, while not expected to be sexual health experts, can provide comprehensive patient-centered care by including sexual health as part of their evaluation. They can explore how sexual dysfunction can impair functioning and utilize an interdisciplinary approach to manage symptoms. Palliative care providers can help patients identify their goals of care and explore what anticipated sexual changes and treat-related side effects are tolerable and intolerable to the patient’s quality of life. Principles on addressing sexuality in the palliative setting and practical ways of incorporating sexual history into the palliative care assessment are provided.
- 15 January 2016
- Published by Springer Nature in Current Oncology Reports
- Vol. 18 (2) , 1-6
Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care
Treatment-related sexual complications are common in cancer patients although rarely discussed in the palliative care setting. Sexuality is an important survivorship issue and remains relevant even in the terminal setting. There are multiple barriers in dialoguing about intimacy and sexual functioning from the patient and provider perspectives. Palliative care providers, while not expected to be sexual health experts, can provide comprehensive patient-centered care by including sexual health as part of their evaluation. They can explore how sexual dysfunction can impair functioning and utilize an interdisciplinary approach to manage symptoms. Palliative care providers can help patients identify their goals of care and explore what anticipated sexual changes and treat-related side effects are tolerable and intolerable to the patient’s quality of life. Principles on addressing sexuality in the palliative setting and practical ways of incorporating sexual history into the palliative care assessment are provided.
- 1 December 2013
- Published by Elsevier in Seminars in Oncology
- Vol. 40 (6) , 726-744
Sexual and Reproductive Health in Cancer Survivors
- 1 December 2013
- Published by Elsevier in Seminars in Oncology
- Vol. 40 (6) , 726-744
Sexual and Reproductive Health in Cancer Survivors
- 1 February 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (2) , 319-325
A National Network to Advance the Field of Cancer and Female Sexuality
Introduction: Understanding sexual health issues in cancer patients is integral to care for the continuously growing cancer survivor population. Aim: To create a national network of active clinicians and researchers focusing on the prevention and treatment of sexual problems in women and girls with cancer. Methods: Interdisciplinary teams from the University of Chicago and Memorial Sloan-Kettering Cancer Center jointly developed the mission for a national conference to convene clinicians and researchers in the field of cancer and female sexuality. The invitee list was developed by both institutions and further iterated through suggestions from invitees. The conference agenda focused on three high-priority topics under the guidance of a professional facilitator. Breakout groups were led by attendees recognized by collaborators as experts in those topics. Conference costs were shared by both institutions. Main Outcome Measure: Development of Scientific Working Groups (SWGs). Results: One hundred two clinicians and researchers were invited to attend the 1st National Conference on Cancer and Female Sexuality. Forty-three individuals from 20 different institutions across 14 states attended, including representation from eight National Cancer Institute (NCI)-funded cancer centers. Attendees included PhD researchers (N = 19), physicians (N = 16), and other healthcare professionals (N = 8). Breakout groups included (i) Defining key life course sexuality issues; (ii) Building a registry; and (iii) Implementing sexual health assessment. Breakout group summaries incorporated group consensus on key points and priorities. These generated six SWGs with volunteer leaders to accelerate future research and discovery: (i) Technology-based interventions; (ii) Basic science; (iii) Clinical trials; (iv) Registries; (v) Measurement; and (vi) Secondary data analysis. Most attendees volunteered for at least one SWG (N = 35), and many volunteered for two (N = 21). Conclusion: This 1st National Conference demonstrated high motivation and broad participation to address research on cancer and female sexuality. Areas of need were identified, and SWGs established to help promote research in this field.
- 1 February 2013
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (2) , 319-325
A National Network to Advance the Field of Cancer and Female Sexuality
Introduction: Understanding sexual health issues in cancer patients is integral to care for the continuously growing cancer survivor population. Aim: To create a national network of active clinicians and researchers focusing on the prevention and treatment of sexual problems in women and girls with cancer. Methods: Interdisciplinary teams from the University of Chicago and Memorial Sloan-Kettering Cancer Center jointly developed the mission for a national conference to convene clinicians and researchers in the field of cancer and female sexuality. The invitee list was developed by both institutions and further iterated through suggestions from invitees. The conference agenda focused on three high-priority topics under the guidance of a professional facilitator. Breakout groups were led by attendees recognized by collaborators as experts in those topics. Conference costs were shared by both institutions. Main Outcome Measure: Development of Scientific Working Groups (SWGs). Results: One hundred two clinicians and researchers were invited to attend the 1st National Conference on Cancer and Female Sexuality. Forty-three individuals from 20 different institutions across 14 states attended, including representation from eight National Cancer Institute (NCI)-funded cancer centers. Attendees included PhD researchers (N = 19), physicians (N = 16), and other healthcare professionals (N = 8). Breakout groups included (i) Defining key life course sexuality issues; (ii) Building a registry; and (iii) Implementing sexual health assessment. Breakout group summaries incorporated group consensus on key points and priorities. These generated six SWGs with volunteer leaders to accelerate future research and discovery: (i) Technology-based interventions; (ii) Basic science; (iii) Clinical trials; (iv) Registries; (v) Measurement; and (vi) Secondary data analysis. Most attendees volunteered for at least one SWG (N = 35), and many volunteered for two (N = 21). Conclusion: This 1st National Conference demonstrated high motivation and broad participation to address research on cancer and female sexuality. Areas of need were identified, and SWGs established to help promote research in this field.
- Open Access
- 1 January 2010
- Published by SAGE Publications in Women's Health
- Vol. 6 (1) , 17-25
Bevacizumab for Advanced Breast Cancer
Tumor angiogenesis is an important step in breast cancer development, progression, invasion and metastasis. Proangiogenic factors such as VEGF regulate angiogenesis and are targets for drug development. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination with either paclitaxel or docetaxel has prolonged progression-free survival and increased response rates in the first-line treatment of patients with metastatic breast cancer. This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer.
- 1 January 2010
- Published by SAGE Publications in Women's Health
- Vol. 6 (1) , 17-25
Open AccessBevacizumab for Advanced Breast Cancer
Tumor angiogenesis is an important step in breast cancer development, progression, invasion and metastasis. Proangiogenic factors such as VEGF regulate angiogenesis and are targets for drug development. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination with either paclitaxel or docetaxel has prolonged progression-free survival and increased response rates in the first-line treatment of patients with metastatic breast cancer. This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer.